RPG Life Sciences · NSE: RPGLIFE · BSE: 532983
Q4 FY25 results · Jan–Mar 2025
RPG Life Sciences reported revenue from operations of ₹143.09 crore (up 12.7% from Q4 FY24) and net profit of ₹117.35 crore (up 786.3% from Q4 FY24) for Q4 FY25 (Jan–Mar 2025), on a standalone basis.
| Item | Q4 FY25 | Q4 FY24 | YoY | Q3 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 143.09 | 126.99 | +12.7% | 172.71 | −17.2% |
| Other income | 5.06 | 1.65 | +206.7% | 3.31 | +52.9% |
| Total income | 148.15 | 128.64 | +15.2% | 176.02 | −15.8% |
| Profit before tax | 134.90 | 17.74 | +660.4% | 46.89 | +187.7% |
| Net profit for the period | 117.35 | 13.24 | +786.3% | 34.93 | +236.0% |
| EPS, basic (₹) | 70.96 | 8.01 | +785.9% | 21.12 | +236.0% |
| Net margin (%) | 82.0 | 10.4 | 20.2 |
Standalone
- Filed with BSE
- 28 Apr 2025, 23:28 IST
- Board meeting
- 28 Apr 2025
- Period
- 01 Jan 2025 to 31 Mar 2025
- Review status
- Audited
- Source
- XBRL filing on BSE